CHARLOTTE, NC and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, the “Company”, “GTG” or “Genetic Technologies”), a global leader in guidance -Tests of based on genomics in health, wellness and serious disease, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 PM ET.
The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insights on the company’s portfolio of genomics-based tests targeting health, wellness and serious disease, including the multi- geneType risk.
The team will provide an update on four key strategies:
-
Scaling of existing sales channels – amplification of existing sales channels to increase market penetration and participation.
-
Aggressive marketing – leveraging our digital initiative to rapidly tap into the growing direct-to-consumer market.
-
Expansion of territories – expanding our global footprint through strategic licensing agreements.
-
Strategic Partnerships – creating partnerships with prominent health systems, exemplified by our recent collaboration with US-based Wellworks and Stay Healthy.
Genetic Technologies is focused on scaling operations by expanding its direct-to-consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+.
To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_OeG7n1jgRQKZp_Ev2Y4R5Q#/registration
Questions can be submitted to GENE@redchip.com or online during the live event.
Authorized for release by the Board of Directors.
Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
GENE@redchip.com
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based testing in health, wellness and critical illness through its geneType and EasyDNA brands. GTG provides predictive cancer testing and evaluation tools to help clinicians improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes for clinicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
Forward-Looking Statements
This announcement may contain forward-looking statements regarding the Company’s expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, whether oral or written. Forward-looking statements may be identified by the use of forward-looking words such as “believe,” “expect,” “aim,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations thereof. words or other comparable words or from the fact that these statements do not deal strictly with historical or current matters. These forward-looking statements may include, but are not limited to, various filings made by the Company with the US Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the executive officers of authorized by the Company. Forward-looking statements relate to events, activities, trends or results anticipated or expected as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. next. Many factors could cause the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the ASX at Australia and the risks and risk factors involved. In addition, the Company operates in an industry sector where securities values are highly volatile and may be affected by economic and other factors beyond its control. The Company undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
#Join #Genetic #Technologies #Exclusive #Direct #Investor #Webinar #Session #June
Image Source : finance.yahoo.com